AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2448657
Drug: CAVP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAVP therapy
Trial: 27567756
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of extended-release theophylline
Trial: 22379743
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline nasal spray
Trial: 18191847
Drug: Progesterone (P)
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone (P) only as luteal support (200 mg bid starting the following night after oocyte retrieval)
Trial: 18191847
Drug: E(2) and
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E(2) and P combined (E(2) patches 100 microg/day twice per week starting on the day of embryo transfer with P)
Trial: 16157525
Drug: Dipyridamole (0.74
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (0.74 mg/kg of body weight) used for coronary flow reserve assessment
Trial: 14503903
Drug: Sling treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sling treatment for shoulder dislocation
Trial: 14503903
Drug: External rotation
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External rotation treatment (splint or pillow)
Trial: 8863556
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg fluoxetine daily for 1 week and 40 mg daily afterward (group 1)
Trial: 8863556
Drug: 1 capsule
RxNorm normalized name: Cebocap 1 Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule placebo daily for 1 week and 2 capsules daily afterward (group 2)
Trial: 1407240
Drug: 1500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg/day calcium supplement
Trial: 18556898
Drug: Sensory integration
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensory integration therapy program
Trial: 16013898
Drug: Modafinil up
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil up to 200 mg a day (N = 13)
Trial: 25842396
Drug: Atomized lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomized lidocaine administered via intranasal mucosal delivery device
Trial: 20497775
Drug: 10-g dose
RxNorm normalized name: lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-g dose of oligofructose
Trial: 20497775
Drug: 5-g dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-g dose of oligofructose
Trial: 20497775
Drug: 10-g dose
RxNorm normalized name: lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-g dose of native inulin
Trial: 20497775
Drug: 5-g dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-g dose of native inulin
Trial: 16176615
Drug: EGCG-caffeine mixtures
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG-caffeine mixtures (200 mg caffeine and variable doses of EGCG: 90, 200, 300, or 400 mg)
Trial: 12949316
Drug: NFV 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NFV 30 mg/kg TID
Trial: 12949316
Drug: NFV 55
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NFV 55 mg/kg BID
Trial: 10755203
Drug: Celiprolol (200‐400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (200‐400 mg daily)
Trial: 10755203
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (unchanged therapy)
Trial: 9063232
Drug: Resin composite
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resin composite with a dentinal bonding agent
Trial: 6348986
Drug: 25% BCAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% BCAA solution
Trial: 21655317
Drug: Caregivers seeking
RxNorm normalized name: PAIN PALLIATION (BONE SEEKING AGENTS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregivers seeking treatment for child's fever
Trial: 16752333
Drug: Cell infusion
RxNorm normalized name: irrigation set MISCELL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell infusion via a perfusion catheter with multiple side holes (SH-PC)
Trial: 6734072
Drug: Intraluminal hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intraluminal hydrocortisone (100 mg/l)
Trial: 6734072
Drug: Intraluminal hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intraluminal hydrocortisone (10 mg/l and 30 mg/l) followed by intravenous hydrocortisone
Trial: 6734072
Drug: Intraluminal hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intraluminal hydrocortisone (100 mg/l) perfused with fructose and bicarbonate
Trial: 25227544
Drug: Position one
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Position one wheelchair configuration (one inch of seat slope, solid backrest mounted at 105 degree seat to back angle, no solid seat insert with gel/foam contoured cushion)
Trial: 21180218
Drug: Dinoprostone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprostone (0.5 mg intracervically)
Trial: 12941196
Drug: Systemic immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic immunotherapy
Trial: 6981575
Drug: Propranolol (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (continuous oral administration, dosage reducing heart rate by 25%)
Trial: 31296586
Drug: Deutetrabenazine, starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deutetrabenazine, starting at 12 mg/day, titrated up to a maximum of 48 mg/day (36 mg/day for patients on strong CYP2D6 inhibitors).
Trial: 22617579
Drug: Combination (clomiphene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (clomiphene citrate and metformin)
Trial: 20650012
Drug: time‐contingent paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: time‐contingent paracetamol (4 g daily in divided doses)
Trial: 20650012
Drug: PRN paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRN paracetamol
Trial: 15848538
Drug: Early cessation
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early cessation of corticosteroid therapy
Trial: 15848538
Drug: Long-term corticosteroid
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term corticosteroid maintenance therapy
Trial: 7622004
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy aimed at maintaining near-normal blood glucose values
Trial: 7622004
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment regimen
Trial: 2143145
Drug: Long-acting GnRH-a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting GnRH-a administered in early follicular phase (group A)
Trial: 2143145
Drug: Long-acting GnRH-a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting GnRH-a administered in midluteal phase (group B)
Trial: 735925
Drug: Physostigmine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (single dose)
Trial: 735925
Drug: Physostigmine (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (long-term treatment)
Trial: 735925
Drug: Physostigmine (sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (sustained treatment for 6 months)
Trial: 735925
Drug: Physostigmine (sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (sustained treatment for 6 to 36 months)
Trial: 28926440
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl 0 μg/ml
Trial: 28926440
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl 1 μg/ml
Trial: 28926440
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl 2 μg/ml
Trial: 28926440
Drug: Cumulative fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cumulative fentanyl dose
Trial: 20632302
Drug: Combined treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatments (taping, strengthening, stretching)
Trial: 17144784
Drug: Selective serotonin-reuptake
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin-reuptake inhibitors
Trial: 8187005
Drug: Six weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Six weekly doses of carboplatin concurrent with radiotherapy
Trial: 31115690
Drug: Intrapapillary injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapapillary injection (IPI)
Trial: 31573398
Drug: Oxygen inhalation
RxNorm normalized name: oxygen INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen inhalation during 0.55 T MRI
Trial: 25929711
Drug: Chin cup
RxNorm normalized name: CHIN-UP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chin cup treatment
Trial: 23521503
Drug: GSK239512 (5/10/20/40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK239512 (5/10/20/40 μg and 10/20/40/80 μg regimens)
Trial: 23521503
Drug: GSK239512 (20/40/80/150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK239512 (20/40/80/150 μg regimen)
Trial: 16875470
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Contractubex gel)
Trial: 9024032
Drug: Epidural dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural dexamethasone (1 mL, 5 mg) with 25 mL 2% lidocaine and epinephrine 1:200,000
Trial: 8395488
Drug: Low-dose Lisinopril
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Lisinopril
Trial: 30412993
Drug: Nature-Based Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nature-Based Therapy (NBT)
Trial: 26154154
Drug: Sequential intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential intermittent pneumatic compression (SIPC)
Trial: 19827029
Drug: 5% extract
RxNorm normalized name: COAL TAR 5% EXTRACT TOP STICK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% extract of Solidago chilensis applied externally as a gel, two daily applications for 15 days
Trial: 19827029
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel applied externally, two daily applications for 15 days
Trial: 11975091
Drug: Reboxetine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (2 x 2 mg)
Trial: 11471032
Drug: alpha‐IFN treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐IFN treatment
Trial: 8732235
Drug: Acarosan treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarosan treatment and bedding covers
Trial: 8732235
Drug: Acarosan treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarosan treatment
Trial: 1374201
Drug: Diclofenac (0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (0.35 mg.kg‐1 bolus followed by a constant‐rate infusion of 90 micrograms.min‐1 for 24 h)
Trial: 3926667
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg dexamethasone (1 ml Decadronphosphate)
Trial: 30770780
Drug: Methylphenidate (MP)
RxNorm normalized name: 6 MP
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MP) 0.5 mg/kg, i.v.
Trial: 27269942
Drug: Pertuzumab (840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pertuzumab (840 mg loading dose followed by 420 mg every 3 weeks)
Trial: 27269942
Drug: Pertuzumab plus
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab plus chemotherapy
Trial: 16472719
Drug: Alcohol ingestion
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol ingestion (60 g of ethanol)
Trial: 8918401
Drug: Oral levo-leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral levo-leucovorin (1-leucovorin) 25 mg/dose followed by oral 5-dFUR 750 mg/m2 twice daily for 4 days every 12 days (arm A)
Trial: 8918401
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) 1-leucovorin 25 mg/dose followed by i.v. 5-dFUR 3000 mg/m2 for 5 days every 21 days (arm B)
Trial: 2981515
Drug: Intermittent long-term
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent long-term combined chemotherapy (ILTCC) with immunotherapy
Trial: 2981515
Drug: Continuous long-term
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous long-term combined chemotherapy (CLTCC) with immunotherapy
Trial: 2981515
Drug: Short-term combined
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term combined chemotherapy (STCC)
Trial: 23263261
Drug: Supervised medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised medical exercise therapy
Trial: 21309475
Drug: Esomeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (20 mg/day) in healthy subjects
Trial: 21309475
Drug: Esomeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (20 mg/day) in patients with a stent
Trial: 10539831
Drug: 600 mg/d
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/d tranilast
Trial: 10539831
Drug: 300 mg/d
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/d tranilast
Trial: 8557899
Drug: Metoprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (200 mg once daily)
Trial: 8557899
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (metoprolol + nifedipine)
Trial: 6285406
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg delta 9‐THC
Trial: 6285406
Drug: Mixture of
RxNorm normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture of 0.5 mg/kg delta 9‐THC and 1 mg/kg CBD
Trial: 24830749
Drug: Daily Co-trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Co-trimoxazole (CTX)
Trial: 15939311
Drug: Ciclesonide 320
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide 320 microg once daily (o.d.)
Trial: 15939311
Drug: Ciclesonide 640
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide 640 microg once daily (o.d.)
Trial: 15939311
Drug: Ciclesonide 640
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide 640 microg twice daily (b.i.d.)
Trial: 15939311
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 440 microg twice daily (b.i.d.)
Trial: 15939311
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 880 microg twice daily (b.i.d.)
Trial: 14568851
Drug: Nerve growth
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve growth factor treatment
Trial: 14568851
Drug: Conventional topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional topical treatment
Trial: 10930151
Drug: ALVAC‐HIV followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALVAC‐HIV followed by the protein vaccine
Trial: 8653191
Drug: Cost recovery
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost recovery intervention with improved drug supply in Say and Boboye
Trial: 25150159
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 300 units · mL(‐1) (Gla‐300) at 0.4 units · kg(‐1)
Trial: 25150159
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 100 units · mL(‐1) (Gla‐100) at 0.4 units · kg(‐1)
Trial: 24511720
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl 1 microg/kg
Trial: 24511720
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 1 ml/10 kg
Trial: 12838218
Drug: 2 L
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L of polyethylene glycol-electrolyte solution, one tablet of bisacodyl, and a minimally restricted diet on the day before colonoscopy, and then 1 L of the same solution on the day of colonoscopy (Group B)
Trial: 12838218
Drug: 3 L
RxNorm normalized name: D3 Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 L of polyethylene glycol-electrolyte solution with a liquid diet on the day before colonoscopy (Group A)
Trial: 10834779
Drug: PCEA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA with 0.1% bupivacaine + fentanyl (3 microg/mL) at 5 mL/h
Trial: 8436747
Drug: Zofenopril (angiotensin-converting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zofenopril (angiotensin-converting enzyme inhibitor)
Trial: 3017605
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 mg b.d.)
Trial: 31468364
Drug: Responders to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responders to MAS therapy
Trial: 27840477
Drug: Classic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classic treatment (control)
Trial: 18257180
Drug: Medication (Mecobalamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Mecobalamin tablets)
Trial: 15927394
Drug: Duloxetine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (all active treatment groups)
Trial: 6988748
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (31 patients) receiving no prophylactic antibiotics
Trial: 25581505
Drug: Tight control
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight control treatment strategy
Trial: 25581505
Drug: Good treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Good treatment strategy
Trial: 25581505
Drug: Good medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Good medication
Trial: 9085316
Drug: Vancomycin 1000
RxNorm normalized name: vancomycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 1000 mg infused during the last hour of hemodialysis with cellulose triacetate (CT) hemodialyzer
Trial: 9085316
Drug: Vancomycin 1000
RxNorm normalized name: vancomycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 1000 mg infused during the last hour of hemodialysis with cellulose acetate (CA) hemodialyzer
Trial: 9085316
Drug: Vancomycin 1000
RxNorm normalized name: vancomycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 1000 mg infused after dialysis was completed (control)
Trial: 3566858
Drug: Fendiline hydrochloride
RxNorm normalized name: fendiline hydrochloride
DrugBank: Fendiline (DB08980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fendiline hydrochloride 200 mg, 400 mg, 600 mg, 800 mg, 1000 mg, 1200 mg (single doses)
Trial: 3566858
Drug: Fendiline hydrochloride
RxNorm normalized name: fendiline hydrochloride
DrugBank: Fendiline (DB08980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fendiline hydrochloride 400 mg twice daily (initially), reduced to 200 mg twice daily after 5 days due to intolerability
Trial: 3566858
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 subjects per dose level in the first study and 3 subjects in the second study)